ERBB2 and neoplasm: In xenograft models overexpressing HER2 (BT474) and EGFR (SKOV-3 and A431), neratinib dose-dependently inhibited tumor growth: almost by ~70–90% in xenografts of BT474, ~30–60% in xenografts of SK-OV-3, and ~32–44% in xenografts of A431 [128].